Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism ALDH2 inhibitors(Aldehyde dehydrogenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H17Cl2N2O6P |
InChIKeySPADNYVJQZNTKZ-UHFFFAOYSA-N |
CAS Registry1416975-42-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 2 | - | Amygdala Neurosciences, Inc.Startup | - |
Opioid-Related Disorders | Phase 2 | - | - | |
Alcohol Use Disorder | Phase 1 | US | 08 Oct 2019 | |
Alcoholism | Phase 1 | US | - | - |
Smoking Cessation | Phase 1 | US | Amygdala Neurosciences, Inc.Startup | - |
Substance-Related Disorders | Phase 1 | US | Amygdala Neurosciences, Inc.Startup | - |
Opium Dependence | Discovery | US | 01 Mar 2019 |
Phase 2 | 43 | (ANS-6637 - 200mg) | foenajrygk(cqlxptbaat) = yoglhmrhkl bccxkbkxns (ldmejpkboj, qjmqtorgak - smidonmgpk) View more | - | 10 Mar 2022 | ||
(ANS-6637 - 600mg) | foenajrygk(cqlxptbaat) = sbhacgtxbv bccxkbkxns (ldmejpkboj, ponzmxlfgv - hdumdljryn) View more | ||||||
Phase 1 | 26 | ozztuhjfhy(ryknslmqlh) = zysbnenwsf xkrdhhglhr (gocrzdswau, lckpjdtpxt - ffryshqqax) View more | - | 03 Aug 2020 |